36 results on '"Bertino, E."'
Search Results
2. Using spatial data access structures for filtering nearest neighbor queries
3. EP13.05-01 Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide.
4. Finitely representable nested relations
5. PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy.
6. PP01.16 Improving Access to Early Palliative Care Delivery for Patients with an Advanced Thoracic Malignancy Through an Embedded Onco-Palliative Clinic Model.
7. EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation.
8. EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy.
9. P2.02-02 A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy.
10. P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome.
11. P75.12 Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy.
12. P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation.
13. OA05.03 Onco-Pall Clinic: An Embedded Care Model for Thoracic Malignancy.
14. OA05.01 Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With an Advanced Thoracic Malignancy.
15. P79.04 A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.
16. P48.19 Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center.
17. P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab.
18. EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center.
19. Unilateral idiopathic chylothorax in malformed newborn: a case report.
20. Design issues in interactive user interfaces
21. An approach to authorization modeling in object-oriented database systems
22. Path-index: An approach to the efficient execution of object-oriented queries
23. The effects of two-phase locking on the performance of a distributed database management system
24. Towards optimal two-dimensional indexing for constraint databases
25. 506PEfficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC).
26. 1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC).
27. 78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors.
28. A10 NEONATAL THROMBOSIS: ANALYSIS OF OUTCOME AT 24 MONTHS IN A SINGLE NEONATAL INTENSIVE CARE UNIT IN THE LAST FIVE YEARS.
29. Counselling in Neonatal Intensive Care Unit (NICU)
30. A lava flow simulation model for the development of volcanic hazard maps for Mount Etna (Italy)
31. Baseline Urinary PGE-M Is a Prognostic and Predictive Marker for Cox-2 Inhibition in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): CALGB 30801 (Alliance): Metastatic Non-Small Cell Lung Cancer.
32. Dynamic-Contrast Enhanced MR and Volume Regression Rate as a Preoperative Predictive Assay in Patients With Non-Small Cell Lung Cancer.
33. A52 URINARY NGAL (NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN) EXCRETION AT BIRTH IS PREDICTIVE OF SUSCEPTIBILITY TO ACUTE KIDNEY INJURY (AKI) IN VERY LOW BIRTH WEIGHT INFANTS.
34. A8 IMPEDANCE PATTERNS IN NEWBORNS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX: IS THERE A CORRELATION WITH CLINICAL OUTCOME?
35. A7 CIRCADIAN VARIABILITY OF GASTROESOPHAGEAL REFLUX IN THE NEWBORN.
36. 603 Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.